Kanazawa Takeharu, Misawa Kiyoshi, Fukushima Hirofumi, Misawa Yuki, Sato Yukiko, Maruta Mikiko, Imayoshi Shoichiro, Kusaka Gen, Kawabata Kazuyoshi, Mineta Hiroyuki, Carey Thomas E, Nishino Hiroshi
Department of Otolaryngology/Head and Neck Surgery, Jichi Medical University, Shimotsuke, Tochigi 329-0498, Japan.
Department of Otolaryngology/Head and Neck Surgery, Jichi Medical University, Saitama Medical Center, Saitama 330-8503, Japan.
Oncol Lett. 2018 Jun;15(6):9043-9050. doi: 10.3892/ol.2018.8525. Epub 2018 Apr 18.
Salivary duct carcinoma (SDC) constitutes one of the most aggressive cancers in the salivary gland and is associated with a poor prognosis; however, no established systemic therapy options are available. SDC exhibits biological similarity to prostate and breast cancers, therefore anti-hormone therapy and molecular target therapies are available, however with limited beneficial effects. Galanin and galanin receptors (GALRs) are well established as molecular biomarkers to predict the survival rate and risk of recurrence of head and neck squamous cell carcinoma. The present study investigated the clinicopathological features of patients with SDC and the methylation status of their galanin and GALR genes to demonstrate the prognostic value for this disease. The median overall survival (OS) was 37.2 months. T-stage, N-stage, disease stage, tumor size, and preoperative facial paralysis were significantly associated with OS, whereas human epidermal growth factor receptor 2 (HER2) overexpression was not. and methylation rates in tumor tissues were significantly increased compared with normal tissues with 9.85- and 4.49-fold increase, respectively. p27 and p57 expression significantly inversely correlated with the methylation rate of and . In addition, the observed and/or methylation rates were significantly correlated with a decrease in OS. These results suggest that and may serve as potential prognostic factors and therapeutic targets in SDC.
涎腺导管癌(SDC)是涎腺中侵袭性最强的癌症之一,预后较差;然而,目前尚无成熟的全身治疗方案。SDC在生物学上与前列腺癌和乳腺癌相似,因此可采用抗激素治疗和分子靶向治疗,但疗效有限。甘丙肽和甘丙肽受体(GALRs)已被确立为预测头颈部鳞状细胞癌生存率和复发风险的分子生物标志物。本研究调查了SDC患者的临床病理特征及其甘丙肽和GALR基因的甲基化状态,以证明其对该疾病的预后价值。中位总生存期(OS)为37.2个月。T分期、N分期、疾病分期、肿瘤大小和术前面神经麻痹与OS显著相关,而人表皮生长因子受体2(HER2)过表达则无相关性。肿瘤组织中的 和 甲基化率与正常组织相比显著增加,分别增加了9.85倍和4.49倍。p27和p57表达与 和 的甲基化率显著负相关。此外,观察到的 和/或 甲基化率与OS降低显著相关。这些结果表明, 和 可能是SDC潜在的预后因素和治疗靶点。